medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Número 1

<< Anterior Siguiente >>

Rev Invest Clin 2015; 67 (1)


Functional Respiratory Assessment in Interstitial Lung Disease

Miguel-Reyes JL, Gochicoa-Rangel L, Pérez-Padilla R, Torre-Bouscoulet L

Idioma: Ingles.
Referencias bibliográficas: 44
Paginas: 5-14
Archivo PDF: 256.47 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J. 2002;19:794-6.

  2. Selman M, Spagnolo P, Richeldi L. Interstitial lung disease in elderly subjects. Eur Resp Mon. 2009;43:150-62.

  3. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-48.

  4. Danoff SK, Terry PB, Horton MR. A clinician’s guide to the diagnosis and treatment of interstitial lung diseases. South Med J. 2007;100:579-87.

  5. ATS/ERS. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277-304.

  6. American Thoracic Society/European Respiratory Society. Update of the International Multidisciplinary Classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-48.

  7. Keir G WA. Assessing pulmonary disease and response to therapy: Which test? Semin Respir Crit Care Med. 2010;31:409-18.

  8. Vargas-Domínguez C, Gochicoa L, Velázquez M. Pruebas de función respiratoria, ¿cuál y a quién? Neumol Cir Torax. 2011; 70:99-115.

  9. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med. 2010;31:409-18.

  10. Aaron SD, Dales RE, Cardinal P. How accurate is spirometry at predicting restrictive pulmonary impairment? Chest. 1999;115: 869-73.

  11. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382-9.

  12. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538-42.

  13. du Bois R WD, Albera C, et al. Forced vital capacity In patients with idiopathic pulmonary fibrosis and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382-9.

  14. Marciniuk DD, Sridhar G, Clemens RE, Zintel TA, Gallagher CG. Lung volumes and expiratory flow limitation during exercise in interstitial lung disease. J Appl Physiol. 1994;77:963-73.

  15. Selman-Lama M, Perez-Padilla R. Airflow obstruction and airway lesions in hypersensitivity pneumonitis. Clin Chest Med. 1993; 14:699-714.

  16. Perez-Padilla R, Torre-Bouscoulet L, Muino A, et al. Prevalence of oxygen desaturation and use of oxygen at home in adults at sea level and at moderate altitude. Eur Respir J. 2006;27:594-9.

  17. Harris-Eze AO, Sridhar G, Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD. Role of hypoxemia and pulmonary mechanics in exercise limitation in interstitial lung disease. Am J Respir Crit Care Med. 1996;154:994-1001.

  18. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis. 1981;124:1-8.

  19. Agusti AG, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez- Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1991;143:219-25.

  20. Hansen JE. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest. 1996;109:1566.

  21. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185:1044-8.

  22. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

  23. Horstman M, Mertens F, Stam H. Transfer factor for carbon monoxide. Eur Resp Mon. 2005;31:127-45.

  24. ATS/ERS TASK FORCE. Standarisation of lung function testing. Eur Respir J. 2005;26:720-35.

  25. Krogh M. The diffusion of gases through the lungs of man. J Physiol. 1915;49:271-300.

  26. Dujic Z, Tocilj J, Eterovic D. Increase of lung transfer factor in early sarcoidosis. Respir Med. 1995;89:9-14.

  27. van der Lee I ZP, Grutters j, Snijder R, van den Bosch J. Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchimal lung disease and pulmonary arterial hypertension. Chest. 2006;129:378-83.

  28. Sandoval J, Lupi E, Gaspar J, Seoane M, Casanova JM. [Active and passive factors in the genesis of pulmonary arterial hypertension in various cardiopathies and pneumopathies]. Arch Inst Cardiol Mex. 1981;51:67-74.

  29. Pitsiou G, Papakosta D, Bouros D. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration. 2011;82: 294-304.

  30. Shlobin OA, Nathan SD. Pulmonary hypertension secondary to interstitial lung disease. Expert Rev Resp. 2011;5:179-89.

  31. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011; 183:1231-7.

  32. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute- walk test. Am J Respir Crit Care Med. 2006;174:803-9.

  33. Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174:659-64.

  34. Lettieria CJ NS, Browninga R, Barnettb S, Ahmadb S, Shorrc A. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. 2006;100:1734-41.

  35. Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology. 2011;16:439-45.

  36. Deboeck G, Scoditti C, Huez S, et al. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J. 2012;40:1410-19.

  37. Fell CD, Liu LX, Motika C, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:402-7.

  38. Zisman DA, Ross DJ, Belperio JA, et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2007; 101:2153-9.

  39. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131:657-63.

  40. Cottin V, Cordier JF. The syndrome of combined pulmonary fibrosis and emphysema. Chest. 2009;136:1-2.

  41. Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35:105-11.

  42. Olson AL SJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007;176:277-84.

  43. Panos RJ MR, Niccoli SA, et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990;88:396-404.

  44. Harari S, Caminati A. Update on diffuse parenchymal lung disease. Eur Respir Rev. 2010;19:97-108.




2020     |     www.medigraphic.com